{"id": "article-25799_0", "title": "Neuroleptic Malignant Syndrome -- Continuing Education Activity", "content": "Neuroleptic malignant syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with rapid withdrawal of dopaminergic medications. NMS has been associated with virtually every neuroleptic agent but is more commonly reported with the typical antipsychotics like haloperidol and fluphenazine. Classic clinical characteristics include mental status changes, fever, muscle rigidity, and autonomic instability. This activity describes the presentation of neuroleptic malignant syndrome and highlights the role of the interprofessional team in the management of affected patients.", "contents": "Neuroleptic Malignant Syndrome -- Continuing Education Activity. Neuroleptic malignant syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with rapid withdrawal of dopaminergic medications. NMS has been associated with virtually every neuroleptic agent but is more commonly reported with the typical antipsychotics like haloperidol and fluphenazine. Classic clinical characteristics include mental status changes, fever, muscle rigidity, and autonomic instability. This activity describes the presentation of neuroleptic malignant syndrome and highlights the role of the interprofessional team in the management of affected patients."}
{"id": "article-25799_1", "title": "Neuroleptic Malignant Syndrome -- Continuing Education Activity", "content": "Objectives: Explain when the diagnosis of neuroleptic malignant syndrome should be considered. Explain how to diagnose neuroleptic malignant syndrome. Explain the management of neuroleptic malignant syndrome. Explore strategies to optimize care coordination among interprofessional team members to improve outcomes for patients affected by neuroleptic malignant syndrome. Access free multiple choice questions on this topic.", "contents": "Neuroleptic Malignant Syndrome -- Continuing Education Activity. Objectives: Explain when the diagnosis of neuroleptic malignant syndrome should be considered. Explain how to diagnose neuroleptic malignant syndrome. Explain the management of neuroleptic malignant syndrome. Explore strategies to optimize care coordination among interprofessional team members to improve outcomes for patients affected by neuroleptic malignant syndrome. Access free multiple choice questions on this topic."}
{"id": "article-25799_2", "title": "Neuroleptic Malignant Syndrome -- Introduction", "content": "Neuroleptic malignant\u00a0syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with the rapid withdrawal of dopaminergic medications. NMS has been associated with virtually every neuroleptic agent but is more commonly reported with the typical antipsychotics like haloperidol and fluphenazine. Classic clinical characteristics include mental status changes, fever, muscle rigidity, and autonomic instability. While uncommon, NMS remains an important part of the differential diagnosis of fever and mental status changes because it requires early diagnosis and treatment to prevent significant mortality and death. Treatment involves immediately discontinuing the offending agent, aggressive supportive care to manage and prevent complications, and pharmacologic therapy in severe cases. The\u00a0empiric medications\u00a0most frequently used for refractory NMS include bromocriptine mesylate, a dopamine agonist, and dantrolene sodium, a muscle relaxant. If the syndrome is due to the rapid withdrawal of dopaminergic medication, rapid re-institution of the medication may improve symptoms. [1] [2] [3]", "contents": "Neuroleptic Malignant Syndrome -- Introduction. Neuroleptic malignant\u00a0syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with the rapid withdrawal of dopaminergic medications. NMS has been associated with virtually every neuroleptic agent but is more commonly reported with the typical antipsychotics like haloperidol and fluphenazine. Classic clinical characteristics include mental status changes, fever, muscle rigidity, and autonomic instability. While uncommon, NMS remains an important part of the differential diagnosis of fever and mental status changes because it requires early diagnosis and treatment to prevent significant mortality and death. Treatment involves immediately discontinuing the offending agent, aggressive supportive care to manage and prevent complications, and pharmacologic therapy in severe cases. The\u00a0empiric medications\u00a0most frequently used for refractory NMS include bromocriptine mesylate, a dopamine agonist, and dantrolene sodium, a muscle relaxant. If the syndrome is due to the rapid withdrawal of dopaminergic medication, rapid re-institution of the medication may improve symptoms. [1] [2] [3]"}
{"id": "article-25799_3", "title": "Neuroleptic Malignant Syndrome -- Etiology", "content": "The primary trigger for NMS is dopamine receptor blockade, most often due to an antipsychotic agent. NMS is usually associated with high-potency first-generation neuroleptic agents but\u00a0also\u00a0may be caused by low-potency and atypical antipsychotic agents, antiemetics, tricyclic antidepressants, and lithium. Rapid withdrawal of dopaminergic drugs, most often used to manage parkinsonian diseases, such as levodopa and amantadine,\u00a0also\u00a0may cause this syndrome. The rapid switching of one Parkinson medication to another also\u00a0is\u00a0associated with the development of NMS. [4] [5] [6]", "contents": "Neuroleptic Malignant Syndrome -- Etiology. The primary trigger for NMS is dopamine receptor blockade, most often due to an antipsychotic agent. NMS is usually associated with high-potency first-generation neuroleptic agents but\u00a0also\u00a0may be caused by low-potency and atypical antipsychotic agents, antiemetics, tricyclic antidepressants, and lithium. Rapid withdrawal of dopaminergic drugs, most often used to manage parkinsonian diseases, such as levodopa and amantadine,\u00a0also\u00a0may cause this syndrome. The rapid switching of one Parkinson medication to another also\u00a0is\u00a0associated with the development of NMS. [4] [5] [6]"}
{"id": "article-25799_4", "title": "Neuroleptic Malignant Syndrome -- Etiology -- Medications Associated with Neuroleptic Malignant Syndrome", "content": "Typical Neuroleptics Haloperidol Chlorpromazine Fluphenazine Thioridazine Trifluordazine Thiothixene Loxapine Bromperidol Promazine Clopenthixol Atypical Neuroleptics Olanzapine Clozapine Risperidone Quetiapine Ziprasidone Aripiprazole Zotepine Amisulpride Antiemetics Droperidol Domperidone Metoclopramide Promethazine Prochlorperazine Others Tetrabenazine Reserpine Amoxapine Diatrizoate Lithium Phenelzine Dosulepin Trimipramine Desipramine Dopaminergic Agents (withdrawal) Levodopa Amantadine Tolcapone Dopamine agonists", "contents": "Neuroleptic Malignant Syndrome -- Etiology -- Medications Associated with Neuroleptic Malignant Syndrome. Typical Neuroleptics Haloperidol Chlorpromazine Fluphenazine Thioridazine Trifluordazine Thiothixene Loxapine Bromperidol Promazine Clopenthixol Atypical Neuroleptics Olanzapine Clozapine Risperidone Quetiapine Ziprasidone Aripiprazole Zotepine Amisulpride Antiemetics Droperidol Domperidone Metoclopramide Promethazine Prochlorperazine Others Tetrabenazine Reserpine Amoxapine Diatrizoate Lithium Phenelzine Dosulepin Trimipramine Desipramine Dopaminergic Agents (withdrawal) Levodopa Amantadine Tolcapone Dopamine agonists"}
{"id": "article-25799_5", "title": "Neuroleptic Malignant Syndrome -- Epidemiology", "content": "Incidence rates range from 0.01% to 3.2% of patients taking neuroleptic medications. The incidence is decreasing due to newer agents, which are less likely to cause NMS, and increased awareness of the condition. Most cases occur in young adults, but this is most likely because it is the age of first exposure to neuroleptic medications rather than an age-related risk. Men outnumber women 2:1, also related to the likelihood of exposure to the causative agent. Incidence due to the withdrawal of dopaminergic drugs is more likely in the geriatric population based on the likelihood of exposure to the inciting cause.", "contents": "Neuroleptic Malignant Syndrome -- Epidemiology. Incidence rates range from 0.01% to 3.2% of patients taking neuroleptic medications. The incidence is decreasing due to newer agents, which are less likely to cause NMS, and increased awareness of the condition. Most cases occur in young adults, but this is most likely because it is the age of first exposure to neuroleptic medications rather than an age-related risk. Men outnumber women 2:1, also related to the likelihood of exposure to the causative agent. Incidence due to the withdrawal of dopaminergic drugs is more likely in the geriatric population based on the likelihood of exposure to the inciting cause."}
{"id": "article-25799_6", "title": "Neuroleptic Malignant Syndrome -- Pathophysiology", "content": "The pathophysiology of NMS is complex and incompletely understood.\u00a0 Most symptoms are attributed to the\u00a0sudden reduction in central dopaminergic activity due to a D2 receptor blockade or abrupt withdrawal of D2 receptor stimulation. This accounts for the characteristic muscle rigidity, hyperthermia, and mental status changes.\u00a0 Other neurotransmitters are involved, and NMS has features suggestive of disruption of the sympathetic nervous system. Other theories suggest a calcium-mediated disruption\u00a0of the musculoskeletal system, pathophysiologically similar to malignant hyperthermia. Familial clusters of patients with NMS and genetic testing suggest\u00a0a\u00a0predisposition to the development of NMS in certain individuals. [7] [8] [9]", "contents": "Neuroleptic Malignant Syndrome -- Pathophysiology. The pathophysiology of NMS is complex and incompletely understood.\u00a0 Most symptoms are attributed to the\u00a0sudden reduction in central dopaminergic activity due to a D2 receptor blockade or abrupt withdrawal of D2 receptor stimulation. This accounts for the characteristic muscle rigidity, hyperthermia, and mental status changes.\u00a0 Other neurotransmitters are involved, and NMS has features suggestive of disruption of the sympathetic nervous system. Other theories suggest a calcium-mediated disruption\u00a0of the musculoskeletal system, pathophysiologically similar to malignant hyperthermia. Familial clusters of patients with NMS and genetic testing suggest\u00a0a\u00a0predisposition to the development of NMS in certain individuals. [7] [8] [9]"}
{"id": "article-25799_7", "title": "Neuroleptic Malignant Syndrome -- History and Physical", "content": "The main risk factor for developing NMS is the initiation or increase in the dosage of neuroleptic medication. High-potency and long-aging neuromuscular depot forms carry the greatest risk. The concurrent use of multiple neuroleptic agents or lithium also increases the risk. Abrupt withdrawal of dopaminergic agents is a less common but important cause of NMS. Symptoms of NMS develop over one to three days and include distinctive clinical features: fever, muscle rigidity, mental status changes, and autonomic rigidity. The DSM-V criteria for diagnosing NMS are as follows:", "contents": "Neuroleptic Malignant Syndrome -- History and Physical. The main risk factor for developing NMS is the initiation or increase in the dosage of neuroleptic medication. High-potency and long-aging neuromuscular depot forms carry the greatest risk. The concurrent use of multiple neuroleptic agents or lithium also increases the risk. Abrupt withdrawal of dopaminergic agents is a less common but important cause of NMS. Symptoms of NMS develop over one to three days and include distinctive clinical features: fever, muscle rigidity, mental status changes, and autonomic rigidity. The DSM-V criteria for diagnosing NMS are as follows:"}
{"id": "article-25799_8", "title": "Neuroleptic Malignant Syndrome -- History and Physical -- Major Criteria (all required)", "content": "Exposure to dopamine-blocking agent Severe muscle rigidity Fever", "contents": "Neuroleptic Malignant Syndrome -- History and Physical -- Major Criteria (all required). Exposure to dopamine-blocking agent Severe muscle rigidity Fever"}
{"id": "article-25799_9", "title": "Neuroleptic Malignant Syndrome -- History and Physical -- Other Criteria (at least two required)", "content": "Diaphoresis Dysphagia Tremor Incontinence Altered level of consciousness Mutism Tachycardia Elevated or labile blood pressure Leukocytosis Elevated creatine phosphokinase", "contents": "Neuroleptic Malignant Syndrome -- History and Physical -- Other Criteria (at least two required). Diaphoresis Dysphagia Tremor Incontinence Altered level of consciousness Mutism Tachycardia Elevated or labile blood pressure Leukocytosis Elevated creatine phosphokinase"}
{"id": "article-25799_10", "title": "Neuroleptic Malignant Syndrome -- Evaluation", "content": "Evaluation should include a comprehensive metabolic panel including electrolytes and serum creatinine, creatine phosphokinase level, urinalysis for myoglobinuria, and arterial or venous blood gas to screen for metabolic acidosis. Diagnosis can be made clinically, but supporting lab work is usually consistent with rhabdomyolysis with an elevated CK and acutely declining renal function. The elevated CK can be profound and typically correlates with disease severity. Leukocytosis is common with white blood cell counts ranging from 10,00 to 40,000 mm3 with a left shift. Transaminases may also be mildly elevated. In patients where the diagnosis is less clear, neuroimaging and lumbar puncture may be necessary to exclude structural and infectious diagnosis from the differential.\u00a0Additional laboratory testing\u00a0such as a lithium level and screening for drugs of abuse may be helpful in selected cases.", "contents": "Neuroleptic Malignant Syndrome -- Evaluation. Evaluation should include a comprehensive metabolic panel including electrolytes and serum creatinine, creatine phosphokinase level, urinalysis for myoglobinuria, and arterial or venous blood gas to screen for metabolic acidosis. Diagnosis can be made clinically, but supporting lab work is usually consistent with rhabdomyolysis with an elevated CK and acutely declining renal function. The elevated CK can be profound and typically correlates with disease severity. Leukocytosis is common with white blood cell counts ranging from 10,00 to 40,000 mm3 with a left shift. Transaminases may also be mildly elevated. In patients where the diagnosis is less clear, neuroimaging and lumbar puncture may be necessary to exclude structural and infectious diagnosis from the differential.\u00a0Additional laboratory testing\u00a0such as a lithium level and screening for drugs of abuse may be helpful in selected cases."}
{"id": "article-25799_11", "title": "Neuroleptic Malignant Syndrome -- Treatment / Management", "content": "NMS is a neurologic emergency, and delays in diagnosis and treatment can lead to significant morbidity or death. Discontinuing the offending agent is paramount, followed by supportive therapy. [10] [11] This includes aggressive cooling and correction of volume deficits and any electrolyte imbalances. Patients are prone to cardiac dysrhythmias and respiratory failure due to chest wall rigidity. Treat with antiarrhythmic agents and mechanical ventilation as needed. More severe cases are managed with empiric pharmacologic therapy. Meta-analyses and case reports suggest that these may shorten the course and reduce morbidity and mortality. Bromocriptine, a dopamine agonist, given orally or via a gastric tube, is used to reverse the hypodopaminergic state.\u00a0Dantrolene, a muscle relaxant may be administered intravenously or orally in less severe cases.\u00a0 Benzodiazepines\u00a0also\u00a0may be useful in controlling agitation. If the syndrome is due to a\u00a0rapid withdrawal of dopaminergic agents, restarting the drug may reduce symptoms. Electroconvulsive therapy\u00a0also\u00a0has been reportedly effective in refractory cases. Patients should be admitted for close monitoring in an intensive care unit setting. [12]", "contents": "Neuroleptic Malignant Syndrome -- Treatment / Management. NMS is a neurologic emergency, and delays in diagnosis and treatment can lead to significant morbidity or death. Discontinuing the offending agent is paramount, followed by supportive therapy. [10] [11] This includes aggressive cooling and correction of volume deficits and any electrolyte imbalances. Patients are prone to cardiac dysrhythmias and respiratory failure due to chest wall rigidity. Treat with antiarrhythmic agents and mechanical ventilation as needed. More severe cases are managed with empiric pharmacologic therapy. Meta-analyses and case reports suggest that these may shorten the course and reduce morbidity and mortality. Bromocriptine, a dopamine agonist, given orally or via a gastric tube, is used to reverse the hypodopaminergic state.\u00a0Dantrolene, a muscle relaxant may be administered intravenously or orally in less severe cases.\u00a0 Benzodiazepines\u00a0also\u00a0may be useful in controlling agitation. If the syndrome is due to a\u00a0rapid withdrawal of dopaminergic agents, restarting the drug may reduce symptoms. Electroconvulsive therapy\u00a0also\u00a0has been reportedly effective in refractory cases. Patients should be admitted for close monitoring in an intensive care unit setting. [12]"}
{"id": "article-25799_12", "title": "Neuroleptic Malignant Syndrome -- Differential Diagnosis", "content": "NMS is one of a group of drug-related acute dysautonomias with common features of fever, rigidity, and autonomic dysfunction. Serotonin syndrome has similar features to NMS and is most easily distinguished by the causative agent, most frequently the serotonin-specific reuptake inhibitors. Hyperthermia and muscle rigidity are usually less severe with serotonin syndrome than with NMS; additionally, serotonin syndrome is more commonly associated with gastrointestinal symptoms, hyperreflexia, and myoclonus. Malignant hyperthermia is almost clinically indistinguishable from NMS, but the history of exposure to depolarizing muscle relaxants, most commonly succinylcholine, or inhaled anesthetic agents make the distinction clear in most cases. Malignant catatonia (MC) may present with fever, rigidity, akinesia, and altered mental status. It is important to distinguish from NMS because\u00a0malignant catatonia\u00a0shows robust responsiveness--reports reveal a full recovery in up to 80% of patients--with rapid initiation of benzodiazepines and electroconvulsive therapy. [13] Distinguishing features of malignant catatonic include increased positive symptoms as compared to NMS and a behavioral prodrome of automatisms, agitation, or psychosis.", "contents": "Neuroleptic Malignant Syndrome -- Differential Diagnosis. NMS is one of a group of drug-related acute dysautonomias with common features of fever, rigidity, and autonomic dysfunction. Serotonin syndrome has similar features to NMS and is most easily distinguished by the causative agent, most frequently the serotonin-specific reuptake inhibitors. Hyperthermia and muscle rigidity are usually less severe with serotonin syndrome than with NMS; additionally, serotonin syndrome is more commonly associated with gastrointestinal symptoms, hyperreflexia, and myoclonus. Malignant hyperthermia is almost clinically indistinguishable from NMS, but the history of exposure to depolarizing muscle relaxants, most commonly succinylcholine, or inhaled anesthetic agents make the distinction clear in most cases. Malignant catatonia (MC) may present with fever, rigidity, akinesia, and altered mental status. It is important to distinguish from NMS because\u00a0malignant catatonia\u00a0shows robust responsiveness--reports reveal a full recovery in up to 80% of patients--with rapid initiation of benzodiazepines and electroconvulsive therapy. [13] Distinguishing features of malignant catatonic include increased positive symptoms as compared to NMS and a behavioral prodrome of automatisms, agitation, or psychosis."}
{"id": "article-25799_13", "title": "Neuroleptic Malignant Syndrome -- Differential Diagnosis", "content": "Multiple other medical conditions can mimic NMS,\u00a0making\u00a0it easy to misdiagnose.\u00a0The most common mimics are central nervous system (CNS) infections such as meningitis or encephalitis, heatstroke, agitated delirium, toxic encephalopathies, withdrawal syndromes, metabolic emergencies, and nonconvulsive status epilepticus.", "contents": "Neuroleptic Malignant Syndrome -- Differential Diagnosis. Multiple other medical conditions can mimic NMS,\u00a0making\u00a0it easy to misdiagnose.\u00a0The most common mimics are central nervous system (CNS) infections such as meningitis or encephalitis, heatstroke, agitated delirium, toxic encephalopathies, withdrawal syndromes, metabolic emergencies, and nonconvulsive status epilepticus."}
{"id": "article-25799_14", "title": "Neuroleptic Malignant Syndrome -- Differential Diagnosis", "content": "Acute encephalitis, meningitis, or brain abscess must be excluded in patients presenting with fever and mental status changes to avoid delay in treatment of CNS infection.\u00a0This involves lumbar puncture for cerebrospinal fluid analysis and neuroimaging in certain cases. Patients on antipsychotic drugs are predisposed to heat-related illnesses, which may\u00a0resemble NMS. Acute intoxication with many recreational drugs such as cocaine, MDMA, amphetamines, methamphetamines, and phencyclidine may have similar features. Abuse of recreational drugs may occur in the setting of medical therapy with antipsychotics making the clinical picture ambiguous. Several withdrawal syndromes may present with features similar to NMS, especially withdrawal from muscle relaxants; the emergence of a withdrawal from an agent like baclofen is best managed by reinitiation therapy or with benzodiazepines. Alcohol and benzodiazepine withdrawal\u00a0also share features with NMS as do the withdrawal syndromes of other sedatives and hypnotics. Thyrotoxicosis and pheochromocytoma\u00a0also have overlapping\u00a0manifestations in common with NMS.", "contents": "Neuroleptic Malignant Syndrome -- Differential Diagnosis. Acute encephalitis, meningitis, or brain abscess must be excluded in patients presenting with fever and mental status changes to avoid delay in treatment of CNS infection.\u00a0This involves lumbar puncture for cerebrospinal fluid analysis and neuroimaging in certain cases. Patients on antipsychotic drugs are predisposed to heat-related illnesses, which may\u00a0resemble NMS. Acute intoxication with many recreational drugs such as cocaine, MDMA, amphetamines, methamphetamines, and phencyclidine may have similar features. Abuse of recreational drugs may occur in the setting of medical therapy with antipsychotics making the clinical picture ambiguous. Several withdrawal syndromes may present with features similar to NMS, especially withdrawal from muscle relaxants; the emergence of a withdrawal from an agent like baclofen is best managed by reinitiation therapy or with benzodiazepines. Alcohol and benzodiazepine withdrawal\u00a0also share features with NMS as do the withdrawal syndromes of other sedatives and hypnotics. Thyrotoxicosis and pheochromocytoma\u00a0also have overlapping\u00a0manifestations in common with NMS."}
{"id": "article-25799_15", "title": "Neuroleptic Malignant Syndrome -- Prognosis", "content": "Early mortality reports were\u00a0greater than 30% for NMS; however, increased awareness, earlier detection,\u00a0and better supportive care have reduced mortality to less than 10%. With early recognition and aggressive treatment, most patients will fully recover in 2\u00a0to 14 days. Delayed treatment may result in significant morbidity such as residual catatonia, parkinsonism, renal, or cardiopulmonary complications. When fatal, deaths are usually due to cardiac arrhythmias, disseminated intravascular coagulation, respiratory failure, or renal failure. Many patients may be successfully restarted on neuroleptic medications, but some will develop recurrent symptoms. Guidelines for re-initiation of neuroleptic therapy recommend waiting at least two weeks after resolution of symptoms, using lower-potency agents, starting with low doses and slowly titrating to effect, and avoiding lithium in conjunction with neuroleptics. Patients should be instructed to avoid dehydration and should be carefully monitored for any symptoms of recurrent NMS.", "contents": "Neuroleptic Malignant Syndrome -- Prognosis. Early mortality reports were\u00a0greater than 30% for NMS; however, increased awareness, earlier detection,\u00a0and better supportive care have reduced mortality to less than 10%. With early recognition and aggressive treatment, most patients will fully recover in 2\u00a0to 14 days. Delayed treatment may result in significant morbidity such as residual catatonia, parkinsonism, renal, or cardiopulmonary complications. When fatal, deaths are usually due to cardiac arrhythmias, disseminated intravascular coagulation, respiratory failure, or renal failure. Many patients may be successfully restarted on neuroleptic medications, but some will develop recurrent symptoms. Guidelines for re-initiation of neuroleptic therapy recommend waiting at least two weeks after resolution of symptoms, using lower-potency agents, starting with low doses and slowly titrating to effect, and avoiding lithium in conjunction with neuroleptics. Patients should be instructed to avoid dehydration and should be carefully monitored for any symptoms of recurrent NMS."}
{"id": "article-25799_16", "title": "Neuroleptic Malignant Syndrome -- Enhancing Healthcare Team Outcomes", "content": "NMS is a medical emergency that is best managed by an interprofessional team. These patients are ideally managed in the ICU with very close nursing monitoring and reporting to the team. A pharmacist trained in toxicology and a toxicologist should be involved in assisting with treatment and management decisions. The key is hydration and supportive therapy. There is no specific drug to reverse this disorder. Anecdotal reports on dantrolene continue to appear but a few case studies indicate that the drug may neither be effective or safe. [14]", "contents": "Neuroleptic Malignant Syndrome -- Enhancing Healthcare Team Outcomes. NMS is a medical emergency that is best managed by an interprofessional team. These patients are ideally managed in the ICU with very close nursing monitoring and reporting to the team. A pharmacist trained in toxicology and a toxicologist should be involved in assisting with treatment and management decisions. The key is hydration and supportive therapy. There is no specific drug to reverse this disorder. Anecdotal reports on dantrolene continue to appear but a few case studies indicate that the drug may neither be effective or safe. [14]"}
{"id": "article-25799_17", "title": "Neuroleptic Malignant Syndrome -- Enhancing Healthcare Team Outcomes", "content": "For most patients in whom the offending drug is discontinued, the prognosis is good. An interprofessional approach to the education of the family, monitoring, and treatment by clinicians, nurses, and pharmacists will provide the best outcomes. [Levell 5]", "contents": "Neuroleptic Malignant Syndrome -- Enhancing Healthcare Team Outcomes. For most patients in whom the offending drug is discontinued, the prognosis is good. An interprofessional approach to the education of the family, monitoring, and treatment by clinicians, nurses, and pharmacists will provide the best outcomes. [Levell 5]"}
{"id": "article-25799_18", "title": "Neuroleptic Malignant Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Neuroleptic Malignant Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}